Study of Virtual Reality-based Medical Device for Patients with Depressive Disorder

Omni C&S

Status: Completed

Conditions: Major Depressive Disorder; Depressive Episode; Depressive Disorder

Treatments: Device: OMNIFIT DTx-MDD; Other: standard treatment

Study type: Interventional

Funder types: Industry

Identifiers

NCT05701345

OMNI_MDD_01

Details and patient eligibility

About

This study apply a wearable visual device (HMD)-VR-based software medical device for patients with depressive disorder for 8 weeks.

The investigator would like to confirm evaluate the safety and efficacy of the wearable visual device(HMD)-VR-based software medical device effect of improving depressive disorder in patients.

Full description

Trial subject is a mild and moderate patients diagnosed with depressive disorder The test group is a wearable visual device(HMD)-VR-based software medical device(OMNIFIT DTx-MDD) and patients who have received standard treatment.

The number of subjects is 162(Two groups, 81 people per group, 15% dropout rate included) Participating institutions are five including Catholic University of Korea Seoul ST.

The clinical trial method is as follows. Subjects who are satisfied with all selection/exclusion criteria and agree to participate in clinical trials are classified into groups that combine test software medical devices and standard treatment based on Visit 2 (Baseline) and groups that perform simple standard treatment. After that, necessary tests are performed at 2, 4, 6, and 8 weeks, and changes in depressive disorder and depressive disorder evaluation scale are confirmed, and safety is evaluated.

Enrollment: 162 patients

Sex: All

Ages: 19 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. right-handed men and women
2. If you agree to participate in this clinical trial and voluntarily sign a written consent form
3. If you can understand and cooperate with the contents of this clinical trial
4. If you have a wireless internet(Wifi) environment
5. Diagnosed by a psychiatrist as major depressive disorder according to the Diagnostic and Statistical Manual of Mental Disorder 5th edition(DSM-5) or other specified depressive disorder
6. Mild or moderate depressive episodes with a total hdrs score of 7 or more and 24 or less
7. If there was no change in the type and dose of antidepressants and antipsychotics taken within 4 weeks prior to participation in this clinical trial

Exclusion criteria

1. if you are pregnant
2. Schizophrenia, schizoaffective disorder, schizophrenic disorder, or a psychotic disorder not otherwise classified or diagnosed in the past
3. If you have current bipolar disorder or have been diagnosed with bipolar disorder in your past history
4. Accompanied by organic mental disorder, epilepsy/convulsive disorder
5. Current eating disorders, alcohol and other substance-related disorders, and obsessive-compulsive disorder
6. Uncontrolled and unstable clinically significant physical condition
7. In cases where psychiatric evaluation and maintenance of treatment are difficult due to other serious acute physical illnesses
8. If you have received electroconvulsive therapy and transcranial magnetic stimulation therapy for a current depressive episode
9. Treatment-resistant depressive disorder for which there was no effect even after using two or more antidepressants in sufficient doses and for a sufficient period of time (6 weeks) for the current depressive episode
10. Currently requiring inpatient treatment for a psychiatric disorder other than depressive disorder (ex. alcohol dependence, substance abuse)
11. If the risk of suicide, self-harm, or other harm is judged to be high according to the evaluation of the study director
12. Current depressive episode accompanied by psychotic symptoms
13. Cases in which a therapeutic intervention for a clinical trial cannot be performed due to deterioration of eyesight or hearing
14. Current treatment with mood stabilizers (lithium, valproate, carbamazepine, lamotrigine) for depressive episodes
15. Those who are unable to participate in clinical trials due to the judgment of other researchers
16. Those who cannot read the consent form (ex. illiterate, foreigners)

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

162 participants in 2 patient groups, including a placebo group

medical device used group

Experimental group

Description:

Wearable visual device(HMD)-VR-based software medical device(OMNIFIT DTx-MDD)

Treatment:

Other: standard treatment

Device: OMNIFIT DTx-MDD

medical device unused group

Placebo Comparator group

Description:

Patients receiving only standard treatment

Treatment:

Other: standard treatment